HC Wainwright Reaffirms Buy Rating for Keros Therapeutics (NASDAQ:KROS)

HC Wainwright reissued their buy rating on shares of Keros Therapeutics (NASDAQ:KROS - Free Report) in a report published on Thursday,Benzinga reports. The firm currently has a $100.00 price target on the stock.

A number of other research firms have also weighed in on KROS. Jefferies Financial Group started coverage on shares of Keros Therapeutics in a report on Tuesday. They set a "buy" rating on the stock. Cantor Fitzgerald initiated coverage on shares of Keros Therapeutics in a research report on Thursday, October 24th. They set an "overweight" rating for the company. Guggenheim began coverage on shares of Keros Therapeutics in a report on Monday, September 23rd. They set a "buy" rating and a $96.00 price objective for the company. Scotiabank started coverage on Keros Therapeutics in a research note on Wednesday, October 16th. They issued a "sector outperform" rating and a $77.00 target price on the stock. Finally, Wedbush raised Keros Therapeutics to a "strong-buy" rating in a research note on Monday. Twelve equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $88.89.

Keros Therapeutics Price Performance

Shares of Keros Therapeutics stock traded up $0.90 on Thursday, reaching $67.35. 303,595 shares of the company traded hands, compared to its average volume of 368,850. Keros Therapeutics has a 52 week low of $27.31 and a 52 week high of $73.00. The company has a 50 day moving average of $57.30 and a 200 day moving average of $51.99. The firm has a market capitalization of $2.53 billion, a PE ratio of -13.09 and a beta of 1.23.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The firm had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative return on equity of 44.73% and a negative net margin of 62,012.55%. The business's revenue was up 4750.0% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.33) earnings per share. As a group, analysts anticipate that Keros Therapeutics will post -4.9 earnings per share for the current year.

Insider Activity at Keros Therapeutics

In other news, Director Carl L. Gordon sold 250,000 shares of the stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $44.01, for a total transaction of $11,002,500.00. Following the completion of the sale, the director now owns 119,522 shares of the company's stock, valued at approximately $5,260,163.22. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 22.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Keros Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of KROS. LMR Partners LLP bought a new position in Keros Therapeutics during the 3rd quarter valued at approximately $213,000. KBC Group NV boosted its position in shares of Keros Therapeutics by 52.0% in the 3rd quarter. KBC Group NV now owns 1,263 shares of the company's stock worth $73,000 after purchasing an additional 432 shares in the last quarter. Victory Capital Management Inc. bought a new stake in shares of Keros Therapeutics in the 3rd quarter worth $216,000. AlphaCentric Advisors LLC purchased a new stake in shares of Keros Therapeutics during the third quarter valued at $465,000. Finally, Emerald Advisers LLC purchased a new position in Keros Therapeutics in the 3rd quarter worth about $9,032,000. 71.56% of the stock is owned by institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.